Calendar

Scrip Awards 2016

Summit Therapeutics win
‘Clinical Advance of the Year’
for CoDIFy trial of ridinilazole
at the 2016 Scrip Awards:

 

web_scripawards

Stocks

Share Price

LSE: SUMM
166.00p -4.00
at 06:15pm GMT 07 Dec 2016

NASDAQ: SMMT
$10.19 -0.08
at 04:00pm ET 07 Dec 2016

Current Programmes

  • C. Difficile Infections banner image

    C. difficile Infection

    Clostridium difficile infection (‘CDI’) is a major healthcare issue in hospitals, long-term care homes, and increasingly in the wider community. It is a serious illness caused by infection of the colon by the bacteria, C. difficile, which produces toxins that cause inflammation, severe diarrhoea and can in the most serious of cases be fatal.

    Read More
  • Duchenne Muscular Dystrophy image boy

    Duchenne Muscular Dystrophy

    Duchenne Muscular Dystrophy (‘DMD’) is a fatal, genetic disease that predominantly affects boys. It has a population of around 50,000 in the developed world and is classified as a rare or orphan disease. DMD is caused by the absence of a protein called dystrophin which is essential in maintaining the healthy function of muscles in the body.

    Currently there is no disease modifying treatment for all patients with DMD.

    Read More